Lyudmila Bazhenova, MD

When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.This is a formidable challenge. Cancer trials were, and remain, notoriously time-consuming to launch, expensive to run, and difficult to enroll patients to. A deeper understanding of cancer biology and the genomics revolution in medicine have changed how we approach clinical research.When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.